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Abstract
Antimalarial drug resistance is a major obstacle to malaria control and eventual elimination. The routine surveillance for
molecular marker of resistance is an efficient way to assess drug efficacy, which remains feasible in areas where malaria
control interventions have succeeded in substantially reducing malaria transmission. Community based asexual parasite
prevalence surveys were conducted annually in sentinel sites in Gaza Province, Mozambique from 2006 until 2010, before,
during and after antimalarial policy changes to artesunate plus sulfadoxine-pyrimethamine in 2006 and to artemether-
lumefantrine in 2008. Genetic analysis of dhfr, dhps, crt, and mdr1 resistant genes was conducted on 3 331 (14.4%)
Plasmodium falciparum PCR positive samples collected over the study period from 23 229 children aged 2 to 15 years. The
quintuple dhfr/dhps mutation associated with sulfadoxine-pyrimethamine resistance increased from 56.2% at baseline to
75.8% by 2010. At baseline the crt76T and mdr186Y mutants were approaching fixation, 96.1% and 74.7%, respectively.
Following the deployment of artemisinin-based combination therapy, prevalence of both these chloroquine-resistance
markers began declining, reaching 32.4% and 30.9%, respectively, by 2010. All samples analysed over the 5-year period
possessed a single copy of the mdr1 gene. The high and increasing prevalence of the quintuple mutation supports the
change in drug policy from artesunate plus sulfadoxine-pyrimethamine to artemether-lumefantrine in Mozambique. As
chloroquine related drug pressure decreased in the region, so did the molecular markers associated with chloroquine
resistance (crt76T and mdr186Y). However, this reversion to the wild-type mdr186N predisposes parasites towards
developing lumefantrine resistance. Close monitoring of artemether-lumefantrine efficacy is therefore essential, particularly
given the high drug pressure within the region where most countries now use artemether-lumefantrine as first line
treatment.
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Introduction
Despite being a readily preventable and treatable disease,
malaria remains a major global health burden [1]. One of the
main factors contributing to this sustained burden is the
emergence and spread of antimalarial drug resistance [2]. In an
attempt to ensure effective treatment as well as delay the
emergence of antimalarial resistance the WHO recommended
that combination therapy using artemisinin derivatives, replace
all monotherapies as first line treatment for uncomplicated
malaria [3]. Artemisinin-based combination therapies (ACTs)
rapidly decrease parasite load, increase cure rate, are effective
against gametocytes (the source of onward transmission of
malaria) and have the potential to delay the emergence and
spread of antimalarial drug resistance [4,5]. However, recent
studies have shown that the spread of resistance markers is not
always impeded by ACT implementation, particularly if resis-
tance to the partner drug had previously been established within
the region [6,7].
Malaria is major cause of morbidity and mortality in
Mozambique, with approximately 6 million cases annually [1].
The Lubombo Spatial Development Initiative (LSDI) malaria
programme using community based indoor residual spraying (IRS)
together with effective malaria treatment was highly successful in
Maputo Province, Mozambique, where malaria prevalence in
children aged 2–14 years declined from between 64 to 87% at
baseline to below 15% after 7 years of intensive malaria control
[7,8,9]. Based on the advances made in Maputo Province, the
malaria programme was extended into neighbouring Gaza
Province in 2006. The intervention focused on community based
IRS as the national Mozambican malaria treatment policy had
already been changed from chloroquine monotherapy to an
artemisinin-based combination therapy.
In Mozambique, first line treatment for uncomplicated malaria
changed from chloroquine to sulfadoxine-pyrimethamine (SP) plus
amodiaquine in 2004 and then to the artemisinin-based
combination (ACT), artesunate plus SP in 2006 [7,10]. Following
the phased pilot implementation of the artesunate plus SP in
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Maputo Province between 2004 and 2006, molecular markers
associated with SP resistance increased dramatically [7], raising
concern over the effective therapeutic lifespan of artesunate plus
SP. This contributed to a further change in national malaria
treatment policy in 2008 when the fixed dose combination of
artemether-lumefantrine became the recommended first line
treatment for uncomplicated malaria. As is not unusual outside
of a research programme, there was some delay in the
implementation of these changes in national malaria treatment
policies in Gaza Province, where full deployment took 1–2 years.
While in vivo clinical trials are considered the gold standard for
measuring drug efficacy, they are very expensive, time consuming,
labour intensive and require a relatively high number of malaria
cases presenting to the study site. In areas where malaria control
measures have succeeded in reducing malaria transmission
intensity substantially, a more feasible manner to monitor drug
efficacy is the routine surveillance for molecular markers
associated with treatment failure. We report on the prevalence
of molecular markers associated with lumefantrine, chloroquine
and SP resistance in the five years since the introduction of ACTs




The study was conducted at 38 sentinel sites across Gaza
Province, southern Mozambique (Figure 1) during annual
community-based cross sectional malaria prevalence surveys from
2006 until 2010. The province encompasses an area of
75 709 km2, with an approximate population of 1.5 million, and
for the study the 7 districts in Gaza Province were grouped into 4
geographic zones. Zones differed in terms of their population
density and level of economic development, with Zone 5 where the
provincial capital is situated being the most developed and Zone 7
having the lowest population density and the least economic
development. Malaria is endemic to the region with transmission
peaking during the rainy season from October to April. The
majority of the reported malaria cases are caused by Plasmodium
falciparum.
Study population and blood sample collection
Finger prick filter paper blood samples were collected during the
annual malaria prevalence surveys from 120 to 150 children (aged
between 2 and #15 years) at each of the 30 sentinel sites spread
across Zones 4, 5 and 6 in Gaza Province, Mozambique (Figure 1),
from 2006 to 2007. In 2008 Zone 7 with 8 additional sentinel sites
was added to the survey area (Figure 1). Capillary blood samples,
blotted on filter paper (3MM Whatman filter paper, Merck
Laboratory Supplies (Pty) Ltd., Durban, South Africa) were air
dried and then individually stored at room temperature in zip-lock
packets containing desiccant. Blood samples were only taken after
informed consent from a parent/guardian had been obtained.
Sample preparation and analysis
Parasite DNA was extracted from the blood spots of participants
found to be rapid test positive (ICTTM, Global Diagnostics, Cape
Town, South Africa, SD Bioline, SD, Korea) using the Chelex
method [11]. Once a sample was confirmed as P. falciparum
positive by qPCR [12], polymorphism analysis of dihyrofolate
reductase (dhfr), dihydropteroate synthetase (dhps), chloroquine
resistance transporter (crt) and multidrug resistance 1 (mdr1) genes
was conducted. Primers, PCR amplification conditions and
restriction endonucleases used to detect polymorphisms in the
dhfr (codons dhfrN51I, dhfrC59R, dhfrS108N, dhfrI164L), dhps
(codons dhpsS436A, dhpsA437G, dhpsK540E and dhpsA581G),
mdr1 (codon mdr1N86Y) and crt (codon crtK76T) genes have been
described previously [13,14,15]. Digestion products separated on a
2% agarose gel using electrophoresis were visualised and
photographed using a MiniBISTM documentation system (BioSys-
tematica, United Kingdom). Codons were classified as either pure
sensitive, pure mutant or mixed (both mutant and sensitive
genotypes present in an individual sample). Genotyping was run in
duplicate, with a third assay being performed on any discordant
results. When calculating overall prevalence of infections with
mutant genotypes, codons with mixed genotypes were grouped
with pure mutant codons. Copy number of the mdr1 gene was
assessed using the qPCR method, primers, probes and qPCR
cycling conditions previously described by Price et al [16]. Every
qPCR run contained two reference DNA samples from D10 and
Fac8 clones, having an mdr1 copy number of 1 and 3 respectively
as well as a no template control.
Statistical analysis
Statistical analysis was performed using Stata 11.0 (Stata
Corporation, College Station, Texas). Univariate analysis and
multiple variable logistic regression were carried out to determine
whether any of the prospectively defined factors (namely age,
gender, fever, sentinel site specific asexual parasite prevalence,
rural vs peri-urban sentinel site, zone, and study year) were
significantly associated with mutation prevalence. Statistical
inference took account of within-sentinel site correlations of
mutational markers and asexual parasite prevalence; analyses were
weighted for the number of PCR positive patients per site using
inverse proportional weights. Confidence limits were set at 95%.
Ethic Statement
Ethical approval for this study was obtained from the South
African Medical Research Council and the Gaza Provincial
Directorate of Health, Mozambique. Blood samples were only
taken if full informed verbal consent from a parent/guardian had
been obtained. The researchers involved in this study, with ethical
approval from South African Medical Research Council and the
Mozambican Ministry of Health opted to obtain of verbal consent
for sample collections, for the following reasons:
1) Prior to sample collection occurring, awareness campaigns
detailing the purpose, date, time and venue of the prevalence
surveys were conducted by community health workers at the
sentinel sites and
2) During sample collection, the purpose of the survey was once
again explained to the parent/guardian by survey staff on a
one to one basis.
The homestead GPS co-ordinates of each parent/guardian
approached to participate in the survey was recorded and a note
was made of the parents/guardians that declined to participate in
the survey. Less than 10% of the parents/guardians approached
declined to give consent.
Children testing positive for malaria were referred to the closest
health facility for appropriate treatment.
Results
Of the 23 229 children surveyed over the five study years, 4 755
(21%) were rapid test positive for P. falciparum. Filter paper blood
samples were collected from 4 440 (93%) rapid test malaria
positive subjects, of which 3 333 (75.1%) were confirmed P.
Antimalarial Resistance Marker Surveillance
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25992
Figure 1. Sentinel Sites and Zones in Gaza Province, Southern Mozambique.
doi:10.1371/journal.pone.0025992.g001
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falciparum positive by qPCR. The falciparum positive samples were
obtained from children with a median age of 6 (IQR 4–9) years, of
which 48.7% were female and 6.3% febrile (auxiliary temperature
$37.5uC). The median age of malaria infected children increased
from 6 (IQR 4–9) years in 2006 to 7 (IQR 5–10) years by 2010. In
2006 the median PCR confirmed asexual parasite prevalence in
Gaza Province was 28% declining to 4% by 2010 (Figure 2).
Baseline asexual parasite prevalence varied considerably among
the sentinel sites (range 5.9 to 78.7% in 2006 and 0.0 to 45.0% in
2010), as did the rate of decrease in parasite prevalence.
Mutant dhfr164L and dhps581G alleles were not detected in any
of the samples analysed over the study period. All samples
analysed had a single copy of the mdr1 gene. Polymorphisms at
codon dhps436 were extremely rare occurring in 1.4% (48/3 331)
of the samples tested and were only observed in samples collected
in 2006. Mixed dhfr, dhps, crt76 and mdr186 alleles were detected in
14.7% (155/3 331), 43.8% (1460/3 331), 17.5% (386/2 205) and
47.1% (1521/3 233) of the samples analysed, respectively.
The dhfr triple haplotype (codons dhfr51I, dhfr59R and dhfr108N)
was close to fixation (98.1%, 1 235/1 259) at baseline and
remained unchanged following the roll out of ACTs within the
region (OR: 1.01; 95% CI: 0.76–1.34; P = 0.950). Given the
fixation of the dhfr triple mutation in the population, prevalence of
parasites carrying the ‘quintuple’ allele (presence of both the dhfr
triple and dhps double mutations), was very similar to the dhps
double mutation prevalence (codons dhps437G and dhps540E). At
baseline 56.2% (708/1 259) of the parasites analysed carried the
quintuple mutation, which increased to 78.5% (314/400) by 2010
(Table 1, Figure 3). Although quintuple mutation prevalence
varied considerably between the different Zones at baseline (37.4%
in Zone 4, 67.5% in Zone 5, 54.3% in Zone 6 and 31.3% in Zone
7), it increased markedly each year across all Zones over the 5-year
study period (OR: 1.21 per year; 95% CI: 1.02–1.46; P = 0.034).
After adjusting for survey year and zone, multiple logistic
regression analysis confirmed that quintuple mutation prevalence
was independently negatively associated with age (OR: 0.89 per
year of age; 95% CI: 0.85–0.93; P,0.0001), and rural vs. peri
urban sentinel sites (OR: 0.59; 95% CI: 0.43–0.79; P = 0.001). A
slight positive association between quintuple mutation prevalence
and sentinel site specific asexual parasite prevalence was found
(OR: 1.01; 95% CI: 1.005–1.02; P = 0.001) in the logistic model
(Table 2). None of the other pre-defined explanatory variables
were found to be associated with quintuple mutation prevalence.
At baseline the crt76T mutant allele was approaching saturation
within the population (96.1%, 616/641). However following the
replacement of CQ with combination treatments in Gaza
Province, prevalence of this mutation declined annually (OR:
0.33 per year; 95% CI: 0.26–0.42; P,0.0001, Figure 3, Table 1)
dropping to 32.36% (100/309) by 2010.
A positive association between crt76T mutation prevalence and
rural vs. peri-urban sentinel sites (OR: 2.25; 95% CI: 1.13–4.47;
P = 0.022) as well as age (OR: 1.13 per year of age; 95% CI: 1.02–
1.26; P = 0.020) was noted in the multiple logistic regression
analysis, after adjusting for survey year, zone and site specific
asexual parasite prevalence. This model showed no association
between crt76T mutation prevalence and sentinel site specific
parasite prevalence (OR: 0.99; 95% CI: 0.97–1.01; P = 0.340), nor
any of the other pre-defined explanatory variables (Table 2).
Most the parasites analysed at baseline carried the mutant
mdr86Y haplotype (74.7%, 931/1 247). Prevalence of this
mutation remained unchanged from baseline in 2007 (OR: 1.31;
95% CI: 0.91–1.90; P = 0.142), but began declining thereafter
(OR: 0.63 per year; 95% CI: 0.55–0.71; P,0.0001, Figure 3,
Table 1), reaching 30.9% (117/379) by 2010. Only age (OR: 1.05
per year of age; 95% CI: 1.01–1.09; P = 0.015) was shown to be
associated with mdr86Y mutation prevalence in the multiple
logistic regression model, after controlling for survey year, zone,
rural vs. urban site and site specific asexual prevalence. None of
these variables appeared to influence mdr86Y mutation prevalence
(Table 2). By 2010 the number of samples carrying mixed
haplotypes at either codon crt76 or mdr86 had decreased markedly
(Figure 4), reflecting a decrease in transmission rate.
Discussion
The success of an integrated malaria initiative is dependent
upon each component of the initiative functioning optimally in its
own right. One of the biggest challenges for most control
Figure 2. Asexual Parasite Prevalence (%) in Gaza Province by Zone and Year.
doi:10.1371/journal.pone.0025992.g002
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programmes is limiting the emergence and spread of antimalarial
drug resistance [17]. Thus the close monitoring of drug efficacy is
vital to allow for the timely implementation of changes in malaria
treatment policy. Changes in antimalarial drug policy in
Mozambique have had a significant effect on the resistant marker
prevalence in Gaza Province.
Following the implementation of an integrated malaria control
programme in Gaza Province, which included community based
IRS operations, definitive diagnosis using rapid diagnostic test kits,
effective treatment with ACTs and Intermittent Preventative
Treatment (IPT) using SP, PCR-confirmed falciparum malaria
prevalence has declined significantly from a mean of 30% pre-
intervention to below 15% after five years of control. The
accumulation of mutations in the dhfr and dhps genes, the targets of
sulphadoxine-pyrimethamine (SP), are associated with SP treat-
ment failure [18]. Three mutations in the dhfr gene (codons
dhfr108N, dhfr51I and dhfr59R), known as the dhfr triple predict
pyrimethamine drug failure while two mutations in dhps gene
(codons dhps437G and dhps540E), called the dhps double are
strongly associated with sulphadoxine treatment failure. Mutations
in the dhfr and dhps genes usually occur a stepwise fashion; however
in East and Southern Africa these mutations have spread via
selective sweeps [18,19]. Parasites carrying all five mutations,
commonly called the quintuple mutation are associated with SP
treatment failure in southern and East Africa [18]. At baseline the
dhfr triple mutation was at fixation (98%) in the population, with
over 50% of the parasites in the regions carrying quintuple
mutations.
Allen and colleagues showed the presence of the quintuple
mutation resulted in a 3-fold increased risk of treatment failure in
neighbouring Maputo Province, after adjusting for treatment arm
(SP monotherapy versus artesunate plus SP), age and temperature
[20]. As seen in Maputo Province [7], the roll out of the artesunate
plus SP did not halt the spread of the SP resistance parasites, with
70% of all parasites analysed in 2010 carrying the quintuple
mutation. Despite these high levels of SP resistance, the dhfrI164L
mutation associated with high pyrimethamine resistant parasite
has not been detected in the region. None the less, the rapid
increase in the prevalence of the quintuple mutation supports the
decision taken by the Mozambican Ministry of Health in 2008 to
replace artesunate plus SP with artemether-lumefantrine. The
sustained high quintuple mutation prevalence in Gaza Province is
Table 1. Quintuple, crt76T and mdr86Y mutation prevalence
(%) by Zone and Year.
Year Zone Mutation Prevalence
Quintuple crt76T mdr186Y
2006 Zone 4 37.5% (116/309) 96.5% (136/141) 79.5% (244/307)
2007 36.5% (19/52) 97.4% (37/38) 78.4% (40/51)
2008 83.2% (84/101) 88.2% (82/93) 82.8% (82/99)
2009 82.8% (77/93) 62.8% (32/51) 53.5% (46/86)
2010 68.2% (30/44) 19.2% (5/26) 48.8% (21/43)
2006 Zone 5 67.5% (390/578) 96.2% (332/345) 74.9% (427/570)
2007 83.3% (340/408) 93.5% (346/371) 78.2% (315/403)
2008 65.1% (142/218) 82.4% (159/193) 71.1% (155/218)
2009 87.1% (210/241) 41.8 (41/98) 55.9% (124/222)
2010 89.6% (147/164) 35.5% (50/141) 30.9% (47/152)
2006 Zone 6 54.3% (202/372) 95.5% (148/155) 70.3% (260/370)
2007 59.9% (139/232) 86.6% (174/201) 72.7% (162/223)
2008 73.2% (79/108) 82.2% (60/73) 53.1% (51/96)
2009 75.9% (82/108) 55.0% (22/40) 52.5% (53/101)
2010 83.85% (109/130) 37.3% (38/102) 25.8% (32/124)
2006 Zone 7 - - -
2007 - - -
2008 31.3% (20/64) 30.0% (18/60) 33.3% (21/63)
2009 51.1% (24/47) 20.0% (7/35) 26.1% (12/46)
2010 45.2% (28/62) 17.5% (7/40) 28.3% (17/60)
doi:10.1371/journal.pone.0025992.t001
Figure 3. Prevalence of quintuple, crt76Tand mdr186Y mutations (%) in Gaza Province by year.
doi:10.1371/journal.pone.0025992.g003
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not unexpected when three facts are taken into consideration.
First, SP is still being used for intermittent preventative treatment
in pregnancy, second, although artemether-lumefantrine was
adopted as first line treatment in 2008, complete deployment of
the drug in Gaza Province was only achieved by 2010 and thirdly,
the use of other antifolate-sulfonamide combinations like cotri-
Table 2. Factors associated with quintuple, crt76T and mdr186Y mutation prevalence in Gaza Province between 2006 and 2010
(within site correlations are taken into account in the estimation of confidence intervals).
Covariate Quintuple Mutation crtK76T mdr1N86Y
OR 95% CI P value OR 95% CI P value OR 95% CI P value
2006 1 1 1
2007 2.50 1.73–3.62 ,0.0001 0.36 0.15–0.86 0.022 1.31 0.91–1.90 0.142
2008 2.48 1.35–4.55 0.004 0.13 0.05–0.31 ,0.0001 0.87 0.53–1.41 0.549
2009 9.17 4.44–18.93 ,0.0001 0.02 0.01–0.06 ,0.0001 0.26 0.14–0.46 ,0.0001
2010 5.92 3.30–10.61 ,0.0001 0.02 0.01–0.05 ,0.0001 0.33 0.20–0.55 ,0.0001
Age (years) 0.89 0.85–0.933 ,0.0001 1.13 1.02–1.26 0.020 1.05 1.01–1.10 0.015
Asexual Parasite Prevalence (%) 1.01 1.01–1.02 0.001 0.99 0.97–1.01 0.340 1.00 1.00–1.01 0.292
Rural vs Peri Urban Sentinel Site 0.59 043–0.79 0.001 2.25 1.13–4.48 0.022 0.92 0.67–1.27 0.592
Zone 4 1 1 1
Zone 5 2.32 1.50–3.58 ,0.0001 1.05 0.55–2.01 0.876 0.73 0.52–1.04 0.079
Zone 6 1.48 0.94–2.33 0.091 0.61 0.29–1.30 0.196 0.60 0.42–0.87 0.008
Zone 7 0.51 0.29–0.90 0.022 0.22 0.07–0.66 0.009 0.36 0.17–0.80 0.014
doi:10.1371/journal.pone.0025992.t002
Figure 4. Prevalence of pure wild, pure mutant and mixed crt76 and mdr186 alleles (%) in Gaza Province by Year and Zone.
doi:10.1371/journal.pone.0025992.g004
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moxazole as prophylaxis against opportunistic infection in HIV/
AIDS patients [21] may contribute to cross-resistance. Other
countries, including India, that have selected artesunate plus SP as
first line therapy should monitor the efficacy of this treatment
closely, given the unusually short useful therapeutic life of SP, even
when used in combination with artesunate.
In contrast to SP resistance makers, the mdr1N86Y mutation
associated with chloroquine resistance (but lumefantrine sensitiv-
ity) declined from 75% at baseline to 31% in 2010. This shift is
likely to be a result of removal of chloroquine drug pressure
following the introduction of ACTs, as seen in Malawi [22].
Mutations in the P falciparium mdr1 gene appear to modulate the
effectiveness of chloroquine, amodiaquine, mefloquine and
lumefantrine [23]. Of the identified mdr1 mutations, the mdr186Y
mutation is most commonly associated with chloroquine and
amodiaquine resistance and sensitivity to mefloquine and
lumefantrine [23,24,25,26]. As an increase in the mdr186N allele
prevalence has been suggested as the first step to lumefantrine
tolerance [27], our results suggest the need for close monitoring of
artemether-lumefantrine efficacy in Mozambique and its neigh-
bouring countries.
The increase in mdr1 copy number associated with in vitro
lumefantrine resistance in South-east Asia [28] was not detected in
any of the samples analysed in this study. Studies in South East
Asia have shown that the amplification of mdr1 gene is associated
with mefloquine [16] and possibly lumefantrine resistance [28].
Our findings support the suggestion that mdr1 amplification is rare
in Africa [23]. This lack of mdr1 amplification may be a
consequence of the high use of chloroquine in Africa, the absence
of mefloquine drug pressure and the relatively short duration of
widespread artemether-lumefantrine use [29].
Multivariable analysis indicated that SP drug pressure was
greater in peri-urban areas and younger children, while chloro-
quine use appears to have been sustained longer in rural areas and
older children. The negative association between quintuple
mutation prevalence and age but positive association between
the crt76T mutation prevalence and age could be an indication of
variable treatment seeking behaviours within Gaza Province; with
younger children diagnosed and treated at health facilities with
artesunate plus SP, while older children may be diagnosed and
treated at home with chloroquine. Our finding of a small but
significant positive association between quintuple mutation
prevalence and sentinel site specific asexual parasite prevalence
contrasts with historical evidence that drug resistance generally
arises and spreads most rapidly in areas of low intensity malaria
transmission, where lack of immunity would be expected to
increase treatment seeking and facilitate the survival of resistant
parasites. One plausible explanation of our unexpected finding
would be that higher drug resistance increases malaria transmis-
sion in these sentinel sites, by increasing gametocyte carriage in
both the primary [30] and recrudescent infections [16].
The molecular make up of malaria parasites responds rapidly to
changes to drug pressure, making the continued monitoring for
polymorphisms associated with drug resistance essential [31].
Despite limited use of artemether-lumefantrine in Gaza Province,
markers associated with resistance/tolerance to lumefantrine are
already present in the population, a consequence of reduced
chloroquine drug pressure. This is particularly concerning as
artemether-lumefantrine has become first line treatment in most
southern African countries, and increased drug pressure can exert
an influence on drug efficacy in neighbouring countries as
previously seen in Mozambique [9] and Swaziland [32].
Results from this study support the decision taken to replace
artesunate plus SP with artemether-lumefantrine, given the
quintuple mutation nearing fixation. The high prevalence of this
mutation also questions the useful therapeutic life of SP
monotherapy for IPT in this region. A recent Tanzanian study
[33] has shown while IPT does not confer any benefit in an area of
widespread resistance, it may increase the odds of fetal anemia.
We therefore recommend the re-evaluation of IPT using SP in
Mozambique. Additionally, in light of the presence of molecular
makers associated with lumefantrine tolerance/resistance in the
population, we strongly support the continued routine surveillance
for antimalarial drug resistance markers to ensure the recent gains
made by the malaria control programme in Gaza Province are
sustained.
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